8-K
filed March 3, 2023, 6:59 PM ET
ticker RKDA
CIK 0001469443
other material
confidence high
sentiment neutral
materiality 0.60
Arcadia Biosciences raises ~$6M in private placement at $9.00/share
Arcadia Biosciences, Inc.
- Sold 666,334 shares (or pre-funded warrants) at $9.00 each, plus Series A and B investment options for up to 666,334 shares each at $9.00.
- Existing warrants with exercise prices from $37 to $301 amended to $9.00 per share, contingent on closing.
- H.C. Wainwright acted as placement agent with 6% fee and 5% placement agent investment options at $11.25.
- Closing expected March 6, 2023; registration rights agreement requires filing by April 3, 2023.
- Proceeds not explicitly stated but gross from shares alone approximately $6 million.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Arcadia Biosciences, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2023-03-02).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Purchasers
- Effective
- 2023-03-02
Exact text from the filing
Also on March 2, 2023 and in connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Arcadia Biosciences, Inc. amended Option Amendment Agreements with the Purchasers (effective 2023-03-02).
- Action
- amendment
- Agreement
- equity purchase
- Counterparty
- the Purchasers
- Effective
- 2023-03-02
Exact text from the filing
Concurrent with the Private Placement, the Company entered into preferred investment option amendment agreements (the “Option Amendment Agreements”) with the Purchasers.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Arcadia Biosciences, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-03-02).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
- Effective
- 2023-03-02
Exact text from the filing
The Company entered into an engagement letter with H.C. Wainwright & Co., LLC (“Wainwright”) dated March 2, 2023 (the “Engagement Letter”), pursuant to which Wainwright agreed to serve as the Company’s exclusive placement agent for certain equity financing transactions, including the Private Placement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Arcadia Biosciences, Inc. entered into Purchase Agreement with certain institutional and accredited investors (effective 2023-03-02).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional and accredited investors
- Effective
- 2023-03-02
Exact text from the filing
On March 2, 2023, Arcadia Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”)
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.